Skip to main content
. Author manuscript; available in PMC: 2021 Jul 28.
Published in final edited form as: Clin Colorectal Cancer. 2019 Jul 2;18(3):192–199.e1. doi: 10.1016/j.clcc.2019.06.006

Fig 2.

Fig 2.

Activity of anti-MSLN immunotoxin on colon cancer cell lines. A. KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability. Vehicle treated cells were normalized to 1, and Staurosporine treated cells were normalized to 0. Each data point measures six treated wells. B. Identical assay for SW48 CRC cell line and C. HTB39 CRC cell line.